199. A Non-Depleting Anti-Cd4 Monoclonal Antibody Suppressed Antibody Responses and Enhanced Efficacy From Gene Therapy in Pompe Disease

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)35212-1
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Elsevier BV

Related search

Monoclonal Antibody Therapy for Non-Malignant Disease

Australian Prescriber
Pharmacology
2006English

Characterization of the in Vitro and in Vivo Properties of CFZ533, a Blocking and Non-Depleting Anti-Cd40 Monoclonal Antibody

American Journal of Transplantation
TransplantationAllergyImmunologyPharmacology
2018English

Robust Antitumor Effects of Combined Anti-Cd4-Depleting Antibody and Anti-Pd-1/Pd-L1 Immune Checkpoint Antibody Treatment in Mice

Cancer immunology research
Cancer ResearchImmunology
2015English

Monoclonal Antibody Therapy

AAOHN Journal
1987English

Anti-Antibody Activity of a Monoclonal Macroglobulin

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1971English

Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates

Molecules
Organic ChemistryMolecular MedicineAnalytical ChemistryTheoretical ChemistryPharmaceutical ScienceMedicineDrug DiscoveryChemistryPhysical
2015English

Anti-Tumor Activity of an Anti-Endoglin Monoclonal Antibody Is Enhanced in Immunocompetent Mice

International Journal of Cancer
Cancer ResearchOncology
2008English

The Effects of an Anti-Cd4 Monoclonal Antibody, Keliximab, on Peripheral Blood CD4+ T-Cells in Asthma

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2001English

Multispecificity of a Recombinant Anti-Ras Monoclonal Antibody

Journal of Molecular Recognition
Structural BiologyMolecular Biology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy